ÓɽðÔó´óѧµÄҽѧ¡¢ÖÆÒ©ºÍ½¡¿µ¿ÆѧÑо¿ËùKenjiro Ono£¨Ð¡Ò°ÏͶþÀÉ£©½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÓëng28ÄϹ¬Öêʽ»áÉçÏàÖú£¬ÀûÓÃпª·¢µÄÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά£¨Lec-PF£©ÕÉÁ¿ÏµÍ³Ö¤Ã÷£¬Óë·Ç°¢¶û´Äº£Ä¬²¡±ÈÕÕ×éÏà±È£¬°¢¶û´Äº£Ä¬²¡»¼Õß´ÓÇá¶ÈÈÏÖªÕÏ°­µ½Çá¶ÈºÍÖضȳմôµÄ¸÷¸ö½×¶ÎÄÔ¼¹ÒºÖеÄLec-PFŨ¶È¶¼ÓÐËùÉý¸ß¡£±ðµÄ£¬ÕâÏîÑо¿»¹·¢Ã÷£¬ÄÔ¼¹ÒºÖÐ Lec-PFµÄŨ¶ÈÓë·´Ó¦Éñ¾­±äÐÔµÄÉúÎï±ê¼ÇÎïÓÐÃ÷ÏÔµÄÏà¹ØÐÔ¡£

ÂØ¿¨Ä¹ÊÇÒ»ÖÖÆæÌصÄË«ÖØ×÷Óÿ¹Ìå£¬³ýÁËÇå³ý°ß¿éÍâ£¬»¹Ñ¡ÔñÐÔ½áºÏµí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά£¨PF£©£¬ÊÇÖÎÁÆ°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆΪÔçÆÚAD£©»¼ÕßµÄÒ»ÖÖÒ©Îï¡£ÕâÏîÑо¿µÄ½á¹û±êÃ÷£¬ÂØ¿¨Ä¹²¶»ñµÄPF£¨Lec-PF£©±£´æÓÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÄÔ¼¹ÒºÖÐ£¬Lec-PFÊÇÒ»Ö־綾µÄ²¡ÀíÂÑ°×£¬»áµ¼ÖÂÉñ¾­ÍËÐÐÐԱ䡣ÕâÏîÑо¿½ÒʾÁËÂØ¿¨Ä¹¼õ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆ¡£

»ùÓÚÕâЩ·¢Ã÷£¬Î´À´¿ÉÄÜÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿ÄÔ¼¹ÒºÖÐLec PFµÄŨ¶È£¬ÒÔÆÀ¹ÀÖÎÁÆЧ¹û¡£±ðµÄ£¬ÓÉÓÚÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂÑ°×µÈÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Ô¤¼ÆÕâЩ·¢Ã÷Ò²¿ÉÓÃÓÚÔ¤²â°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÔ¤ºó¡£

ÕâÏîÑо¿ÓÚ2025Äê1ÔÂ6ÈÕ18:30£¨ÃÀ¹ú¶«²¿±ê׼ʱ¼ä£©Ðû²¼ÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶Annals of Neurology¡·µÄÍøÂç°æÉÏ¡£

Ñо¿Åä¾°ºÍÄ¿µÄ

µí·ÛÑùÂÑ°×¼¶Áª¼Ù˵ÊǹØÓÚAD²¡ÒòµÄÖ÷ÒªÀíÂÛ£¬¸Ã¼Ù˵ÈÏΪ¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©ÔÚÉñ¾­ÔªÍâÒì³£¾Û¼¯£¬ËæºóÐγÉtauÉñ¾­Ô­ÏËά²ø½á£¬¶ÔÉñ¾­ÔªÔì³ÉËðÉË£¬²¢µ¼Ö¼²²¡±¬·¢¡£Ô­ÏËάÐÎ̬µÄ¦Âµí·ÛÑùÂÑ°×±ÈÏËάºÍ°ß¿éÐÎ̬¸ü¾ßÉñ¾­¶¾ÐÔ£¬ºóÕßÊÇÒì³£¾Û¼¯A¦ÂµÄ×îºó½×¶Î£¬Òò´ËÈÏΪPF¿ÉÄܻᵼÖÂÉñ¾­ÍËÐÐÐԱ䣨²Î¿¼ÎÄÏ×£ºAmin LºÍHarris DA.2012£©¡£ÂØ¿¨Ä¹ÊÇÒ»ÖÖ¿¹µí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά¿¹Ìå£¬×Ô2023ÄêÒÔÀ´Ò»Ö±ÓÃÓÚÖÎÁÆÔçÆÚAD¡£È»¶ø£¬´ËǰûÓйØÓÚÕÉÁ¿ÈËÀàÉúÎïÑù±¾ÖÐPFŨ¶ÈµÄ±¨¸æ£¬²¢ÇÒ×÷ΪÂØ¿¨Ä¹ÖÎÁưеãµÄPFÔÚÕû¸öADÁ¬ÐøÌåÖеÄÂþÑÜÇé¿öÉв»Çå³þ¡£

ÔÚÕâÏîÑо¿ÖÐ£¬Ñо¿Ð¡×éʹÓÃпª·¢µÄ¸ßÁéÃô¶ÈLec-PFÕÉÁ¿ÏµÍ³£¬ÕÉÁ¿ÁËÁÙ´²Ç°AD¡¢ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍAD³Õ´ôÊÜÊÔÕßÒÔ¼°SNAP£¨ÒÉËÆ·ÇAD²¡ÀíÉúÀíѧ£©»¼ÕߺÍÈÏÖª¹¦Ð§Õý³£ÕßµÄÈËÄÔ¼¹Òº£¨CSF£©ÖÐLec-PFµÄŨ¶È£¬²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42Á׵ĹØϵ¡¢ ²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42¡¢Á×Ëữtau£¨p-tau£©181£¨*9£©¡¢p-tau 217¡¢×ÜtauºÍÉñ¾­Á£ÂÑ°×Ö®¼äµÄ¹Øϵ¡£

Ñо¿½á¹û×ÛÊö

ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­»ò³Õ´ô»¼Õߣ¨Í¼1ÖеÄMCI+¡¢AD+×飩µÄLec PF CSFŨ¶ÈÃ÷ÏÔ¸ßÓÚÈÏÖª¹¦Ð§Õý³£µÄ»¼Õߣ¨Í¼ÖеÄYNCºÍAMC×飩¡£

¶ÔÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓëÆäËûÄÔ¼¹Òº±ê¼ÇÎA¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×Ütau¡¢Éñ¾­¿ÅÁ£ÂÑ°×£©Ö®¼ä½øÐÐÁËÏà¹ØÐÔÆÊÎö¡£Í¼2ÏÔʾÁËLec PFºÍÖÖÖÖCSF±ê¼ÇÎïÖ®¼äµÄSpearmanÏà¹ØϵÊý£¨95%ÖÃÐÅÇø¼ä£©¡£ÔÚËùÓÐÊÜÊÔÕßÖУ¨Í¼2ÖеĺÚÏߣ©£¬ÄÔ¼¹ÒºÖÐLec PFŨ¶ÈÓëa¦Â42¡¢a¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׳ÊÏà¹ØÐÔ£¬SpearmanϵÊýΪ0.2»ò¸ü¸ß¡£ÖµµÃ×¢ÒâµÄÊÇ£¬µ±½ö¹Ø×¢A¦ÂÑôÐÔ×éʱ£¨Í¼2ÖеĺìÏߣ©£¬Lec PFÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂÑ°×£¨A¦Â¼¶ÁªÖÐA¦ÂÏÂÓεÄÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎÌåÏÖ³öºÜÇ¿µÄÏà¹ØÐÔ£¨SpearmanϵÊýΪ0.4»ò¸ü¸ß£©£¬ÕâÊÇADµÄ²¡Àíѧ¸Ä±ä£¬±êÃ÷Lec PFÊÇÒ»ÖÖÓëÉñ¾­ÍËÐÐÐÔ¼²²¡Ïà¹ØµÄ¾ç¶¾²¡ÀíÂѰס£

δÀ´Éú³¤

ÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿CSFÖеÄLec-PFŨ¶È¿ÉÄÜÓÐÖúÓÚÆÀ¹ÀÂØ¿¨Ä¹ÖÎÁƵÄÁÆЧ¡£±ðµÄ£¬ÓÉÓÚCSFÖÐLec-PFµÄŨ¶ÈÓëÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Òò´ËËüÒ²¿ÉÄÜÓÐÖúÓÚÔ¤²âAD»¼ÕßµÄÔ¤ºó¡£

±¾Ñо¿»ñµÃÁËÈÕ±¾Ò½Ñ§Ñо¿¿ª·¢»ú¹¹£¨AMED£©³Õ´ôÖ¢Ñо¿ÓëÉú³¤×ÊÖú£¨×ÊÖúºÅ22dk0207053£©¡¢×ªÐÍÑо¿×ÊÖú£¨×ÊÖú±àºÅ23H03850£©ºÍ¿ÆѧÑо¿×ÊÖú£¨Åú×¼ºÅJP19k07965¡¢JP22k07514£©µÈÏîÄ¿µÄÖ§³Ö¡£

ͼ 1 ƾ¾ÝÁÙ´²Õï¶ÏºÍµí·ÛÑùÂÑ°×ÑôÐÔ/ÒõÐÔ·ÖÀàµÄÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×Ô­ÏËά£¨CSF Lec-PF£©Å¨¶È

ͼ 1 ˵Ã÷

·½¿òͼÖеķ½¿òÌåÏÖËÄ·ÖλÊý¼ä¾à£¬Ë®Æ½ÏßÌåÏÖÖÐλÊý¡£¸÷×éËõд£º YNC£¨ÄêÇáÕý³£±ÈÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢AMC£¨ÄêÁäÆ¥Åä±ÈÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CI-£¨ÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CU+£¨ÈÏÖª¹¦Ð§Î´ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢MCI+£¨Çá¶ÈÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢AD+£¨AD ³Õ´ô×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢CSF£¨ÄÔ¼¹Òº£©¡£

*p < 0.05

ͼ 2 ÄÔ¼¹Òº±ê¼ÇÎïÓëÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×Ô­ÏËά£¨CSF Lec-PF£©µÄÏà¹ØÐÔ

ͼ2˵Ã÷

ºÚÏߺͺìÏß»®·ÖÌåÏÖÕû¸öÊÜÊÔÕß×éºÍµí·ÛÑùÂÑ°×ÑôÐÔÊÜÊÔÕß×éCSF Lec-PFÓë¸÷ÄÔ¼¹Òº±ê¼ÇÎïÖ®¼ä˹Ƥ¶ûÂüÏà¹ØϵÊýµÄ95%ÖÃÐÅÇø¼ä (CI)¡£ºÚµãºÍºìµãÌåÏÖ˹Ƥ¶ûÂüÏà¹ØϵÊýµÄÖÐÖµ¡£ºÚÏߺͺìÏßÖ®¼äµÄ¾Þ´ó²î±ð·´Ó¦ÁËA¦Â ÑôÐÔ»òÒõÐÔ״̬µÄÏÔÖøÓ°Ïì¡£

ÔÚÕâÏîÆÊÎöÖÐ£¬ËùÓÐÊÜÊÔÕߣ¨ºÚÏߣ©µÄCSF Lec-PFÓëËùÓвⶨµÄÉúÎï±ê¼ÇÎ¼´A¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau 217¡¢×Ü-tauºÍÉñ¾­¿ÅÁ£ÂÑ°×£©Ö®¼äµÄÏà¹ØϵÊý¾ùΪ0.2»ò¸ü¸ß£¬±êÃ÷ CSF Lec-PF ÓëÕâЩÉúÎï±ê¼ÇÎïÖ®¼ä±£´æÏÔÖøÏà¹ØÐÔ¡£ÔÚµí·ÛÑùÂÑ°×ÑôÐÔ×飨ºìÏߣ©ÖÐ£¬CSF Lec-PFÓëCSF total-tauµÄSpearmanÏà¹ØϵÊý»®·ÖΪ0.634£¨CI£º0.409-0.786£©£¬CSF Lec-PFÓëCSF neurograninµÄSpearmanÏà¹ØϵÊý»®·ÖΪ0.434£¨CI£º0.260-0.581£©£¬±êÃ÷CSF Lec-PFÓëÕâÁ½ÖÖÉúÎï±ê¼ÇÎïÖ®¼ä±£´æºÜÇ¿µÄÏà¹ØÐÔ¡£ÁíÒ»·½Ãæ£¬CSF Lec-PFÓëÄÔA¦ÂÀÛ»ýÉúÎï±ê¼ÇÎïCSF A¦Â42ºÍCSF A¦Â42/40±ÈÖµÖ®¼äµÄÏà¹ØÐÔ¶¼Ïà¶Ô½ÏµÍ¡£Õâ±êÃ÷£¬CSF Lec-PFµÄº¬Á¿ÓëÉñ¾­ÍËÐÐÐÔ±äµÄ¹Øϵ±È´óÄÔÖÐA¦ÂµÄ»ýÀÛ¸üΪÃÜÇС£

 

ÎÄÕ·¢ÐÄÇé¿ö£º

ÆÚ¿¯Ãû³Æ£ºAnnals of Neurology

ÎÄÕÂÌâÄ¿: Lecanemab-associated amyloid-¦Â protofibril in cerebrospinal fluid correlates with

biomarkers of neurodegeneration in Alzheimer¡¯s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)

×÷Õß: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono

Ðû²¼ÈÕÆÚ£ºJanuary 6, 2025 (US Eastern Standard Time).

DOI: 10.1002/ANA.27175

 

ÐÅÏ¢ÁªÂ磺

¡ö Regarding research content

Kanazawa University

Professor Kenjiro Ono

TEL: +81-(0)76-265-2292

Email: onoken@med.kanazawa-u.ac.jp

Associate Professor Moeko Shinohara

TEL: +81-(0)76-265-2292

Email: m-nohara@med.kanazawa-u.ac.jp

Eisai Co., Ltd.

Kanta Horie

E-mail: kanta_horie@eisai.com

¡ö Public Relations Officer

General Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences

Administration Department, Kanazawa University

Rina Yamada

TEL: +81-(0)76-265-2109

E-mail: t-isomu@adm.kanazawa-u.ac.jp

Eisai Co., Ltd. PR Department

TEL: +81-(0)3-3817-5120

±àºÅ£ºECN2025-0002

¸»Ê¿Èð±ØÅ·¿Ø¹É¹«Ë¾Óëng28ÄϹ¬Öêʽ»áÉçÅäºÏÐû²¼£¬Ë«·½ÒÑÇ©ÊðÏàÖú±¸Íü¼£¬Ö¼ÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÁìÓò¿ªÕ¹Ñª»ùÐÂÐÍÉúÎï±ê¼ÇÎïµÄÁªºÏÑо¿ºÍÉç»áÍƹã¡£

¸»Ê¿Èð±ØÅ·Óëng28ÄϹ¬Ò»Ö±ÔÚ¿ªÕ¹¹ØÓÚ°¢¶û´Äº£Ä¬²¡£¨AD£©ÄÔ¼¹ÒºÉúÎï±ê¼ÇÎïµÄÁªºÏÑо¿¡£

Á½¼Ò¹«Ë¾¸æ¿¢¹²Ê¶£¬ÈÏΪͨ¹ýÈںϸ»Ê¿Èð±ØÅ·ÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÁìÓòÉîºñµÄ¼ì²âÊÔ¼ÁÑз¢¾­ÑéºÍng28ÄϹ¬ÔÚ³Õ´ôÖ¢ÖÎÁÆÒ©ÎïÑз¢·½ÃæµÄר³¤£¬Äܹ»ÏÔÖø¼ÓËÙÉñ¾­ÍËÐÐÐÔ¼²²¡Õï¶ÏÒªÁìµÄ¿ª·¢ÓëÉÌÒµ»¯³ÌÐò¡£Îª´Ë£¬Ë«·½¼Æ»®ÉîÈë̽Ë÷¶à·½ÃæµÄÏàÖú»úÔµ£¬°üÀ¨Íƶ¯Ñª½¬Á×Ëữtau217ÂÑ°×£¨p-Tau217£©Õï¶ÏÊÔ¼ÁµÄÁÙ´²Ó¦ÓÃ£¬ÀûÓÃÐÂÐÍѪҺÉúÎï±ê¼ÇÎïÑз¢¼ò±ãÒ×ÐеÄÕï¶ÏÊÖ¶Î£¬ÒÔ¼°ÌåÍâÕï¶Ï¼¼ÊõµÄ¿ª·¢ÓëÊг¡Íƹã¡£

¸»Ê¿Èð±ØÅ·ºÍng28ÄϹ¬½«Í¨¹ýÕâÒ»·ÇÅÅËûÐÔÏàÖú¹Øϵ£¬ÅäºÏ½¨Á¢Õë¶ÔÖÖÖÖδÂú×ãÒ½ÁÆÐèÇóµÄÉñ¾­ÍËÐÐÐÔ¼²²¡µÄÕï¶Ï¼¼Êõ£¬²¢¼ÓËÙÕâЩ¼¼ÊõÔÚÈ«ÇòµÄÍƹã¡£´Ë¾ÙÖ¼ÔÚ¹¹½¨Ò»¸öÄܹ»Ñ¡ÔñºÍÌṩÊʵ±ÖÎÁƵÄÇé¿ö£¬½ø¶øΪ¸ÄÉÆÉñ¾­ÍËÐÐÐÔ¼²²¡µÄÕï¶ÏÓëÖÎÁÆ×ö³ö»ý¼«Ð¢¾´¡£

2024Äê12ÔÂ11ÈÕ£¬¸´µ©´óѧ»ù´¡Ò½Ñ§Ôº2023-2024ѧÄê¹ÚÃû½±Ñ§½ð°ä½±ÒÇʽÔÚ·ãÁÖУÇø¸´ÐÇ¥һ¥±¨¸æÌü¡ÖؾÙÐС£ng28ÄϹ¬Öйú¸±×ܲÃÀîÔÆÁú¡¢ÄÏÖйú×¼È벿¸ß¼¶²¿³¤ÂíÏþ·å¡¢¸´µ©´óѧ½ÌÓýÉú³¤»ù½ð»áÃØÊ鳤ÁõÀò¡¢»ù´¡Ò½Ñ§Ôºµ³Î¯Êé¼ÇÕÅÍþ¡¢ÉÏÒ½µ³Î¯Ñ§ÉúÊÂÇ鲿¸±²¿³¤ÓÚר×Ú¡¢»ù´¡Ò½Ñ§Ôºµ³Î¯¸±Êé¼ÇÕÅÀØ¡¢»ù´¡Ò½Ñ§ÔºÁ¢Òìƽ̨Ö÷ÈβÌÆôÁ¼³öϯ±¾´Î°ä½±ÒÇʽ¡£

Ê®ÄêÊ÷ľ£¬°ÙÄêÊ÷ÈË¡£ng28ÄϹ¬Öйúºã¾ÃÖÂÁ¦ÓÚÔö½øÖйú¸ßµÈÒ½Ò©½ÌÓýÊÂÒµÉú³¤£¬ÀîÔÆÁúÔÚÒÇʽÉÏÌåÏÖ£º¡°ng28ÄϹ¬ÖйúÒ»Ö±½«ÌåÌùÈËÀཡ¿µ£¨¼´¡®hhc¡¯£¬human health care£©×÷ΪÆóÒµµÄ×ÚÖ¼£¬ÎÒÃÇÉî֪ҽѧÈ˲ŹØÓÚÌáÉýÈ«Ãñ½¡¿µË®Æ½µÄÖØÒªÐÔ¡£¸´µ©´óѧ»ù´¡Ò½Ñ§Ôºng28ÄϹ¬Öйú½±Ñ§½ð×Ô2007ÄêÉèÁ¢ÖÁ½ñ½ü20ÔØ£¬Îª½üǧÃûÓÅÐãµÄ¸´µ©Ñ§×ÓÌṩ֧³Ö¡£Ï£Íû¸´µ©´óѧ»ù´¡Ò½Ñ§ÔºµÄÓÅÐãѧÉúÔÚδÀ´µÄҽѧÃÅ·ÉÏÄܹ»ÓÂÍùֱǰ£¬ÎªÖйúµÄÒ½Ò©ÊÂÒµ×ö³ö¸ü´óµÄТ¾´¡£¡±

ÏÖ³¡£¬ÀîÔÆÁú¡¢ÂíÏþ·åΪ»ñµÃng28ÄϹ¬Öйú½±Ñ§½ðµÄѧÉúÐû²¼»ñ½±Ö¤Êé¡£ÕâЩÓÅÐãµÄѧÉú²»µ«ÔÚѧϰÉÏÈ¡µÃÁËÓÅÒìµÄ½á¹û£¬¸üÔÚ¿ÆÑС¢Éç»áʵ¼ùµÈ·½ÃæÕ¹ÏÖ³öÁË׿ԽµÄ²Å»ªºÍÁìµ¼ÄÜÁ¦¡£ËûÃǵÄÉú³¤ºÍ½ø²½£¬ÕýÊÇng28ÄϹ¬Öйú½±Ñ§½ðÏîÄ¿ËùÆÚÍû¿´µ½µÄ½á¹û¡£

ÔÚÒÇʽµÄ×îºó£¬ÕÅÍþ¶Ông28ÄϹ¬ÖйúµÄ¿¶¿®¾èÔùºÍÖ§³ÖÌåÏÖÁËÖÔÐĵÄлл¡£ËýÌåÏÖ£º¡°ng28ÄϹ¬ÖйúÒ»Ö±ÒÔÀ´¶¼ÊÇÎÒÃÇѧԺµÄÖØÒªÏàÖúͬ°é£¬ng28ÄϹ¬ÖйúµÄÉƾÙÊÇÒ»·ÝÉîÔ¶µÄÐÅÈÎ£¬¸üÊÇÒ»ÖÖ¶ÔδÀ´µÄͶ×Ê£¬Õâ·ÝÐÅÈοçÔ½Á˸öÈË£¬»ã¾Û³ÉÉç»á¶Ôҽѧ½ÌÓýºÍÈ˲ÅÅàÑøµÄÅäºÏÆÚÅΡ£¡±

ng28ÄϹ¬ÖйúÓ븴µ©´óѧ»ù´¡Ò½Ñ§ÔºµÄÏàÖúÀúÊ·ÓƾÃ£¬ng28ÄϹ¬Öйú´Ó2007Ä꿪ʼÔÚ¸´µ©´óѧ»ù´¡Ò½Ñ§ÔºÉèÁ¢½±Öúѧ½ðÏîÄ¿¡°¸´µ©´óѧ»ù´¡Ò½Ñ§Ôºng28ÄϹ¬Öйú½±Ñ§½ð¡±£¬ÖÁ½ñÒѻݼ°600ÓàÃû»ù´¡Ò½Ñ§ÔºµÄѧÉú£¬ÀÛ¼Æ×ÊÖú½ð¶î¸ß´ï180ÍòÔªÈËÃñ±Ò¡£

¾Ýͳ¼Æ£¬×Ô2000ÄêÖÁ2023Äê£¬ng28ÄϹ¬ÖйúÒÑÔÚÖйú½±ÀøºÍ×ÊÖúÁè¼Ý10ËùÒ½Ò©Àà¸ßµÈԺУѧÉú3186ÈË´Î£¬×ܼƽ±Àø×ÊÖú½ð¶î1074.4ÍòÈËÃñ±Ò¡£ng28ÄϹ¬Öйú½±Öúѧ½ð¼Æ»®ÊÇΪÁËÔö½øÖйú¸ßµÈÒ½Ò©½ÌÓýÊÂÒµµÄÉú³¤£¬½±ÀøÓÅÐãѧÉúºÍ×ÊÖú¼ÒÍ¥À§ÄѵÄѧÉú˳ÀûÍê³Éѧҵ£¬ÎªÉç»áÅàÑø¸ü¶àҽҩѧרҵÈ˲Å¡£³ýÁËÐû²¼½±Ñ§½ðÍâ£¬ng28ÄϹ¬Öйú»¹»ý¼«¼ÓÈëÖÖÖÖҽѧ½ÌÓýÔ˶¯£¬Óë¸ßУÏàÖú¿ªÕ¹¿ÆÑÐÏîÄ¿£¬Íƶ¯Ò½Ñ§½ÌÓýµÄÁ¢ÒìÓëÉú³¤¡£ng28ÄϹ¬Öйú½«¼ÌÐø¼á³ÖÕâÑùµÄÈȳÀ£¬ÒÔʵ¼ÊÐж¯¼ùÐÐ ¡°ÌåÌùÈËÀཡ¿µ¡±hhc(human health care)µÄÆóÒµ×ÚÖ¼¡£

Ëæ×Å°ä½±ÒÇʽµÄÔ²ÂúÂäÄ»£¬ng28ÄϹ¬Öйú½«¼ÌÐø±ü³Ö¡°ÌåÌùÈËÀཡ¿µ¡±µÄÆóÒµ×ÚÖ¼£¬ÖÂÁ¦ÓÚΪÖйúҽѧ½ÌÓýÊÂÒµµÄÉú³¤Ð¢¾´¸ü¶àµÄÁ¦Á¿¡£Í¬Ê±£¬ÎÒÃÇÒ²ÆÚ´ýןü¶àµÄÓÅÐãѧÉúÄܹ»ÔÚng28ÄϹ¬ÖйúµÄÖ§³ÖÏÂ£¬Éú³¤ÎªÎ´À´µÄҽѧ¶°ÁºÖ®²Å£¬ÎªÖйúµÄÒ½Ò©ÊÂÒµ×ö³ö¸ü´óµÄТ¾´£¡

ng28ÄϹ¬ºÍ²³½¡ÁªºÏÐû²¼£¬ÈËÔ´»¯¿ÉÈÜÐÔ¾Û¼¯ÐԦµí·ÛÑùÂÑ°×£¨A¦Â£©µ¥¿Ë¡¿¹ÌåÂØ¿¨Ä¹ÔÚº«¹úÉÌÒµÉÏÊС£ÂØ¿¨Ä¹ÓÚ2024Äê5Ô»ñµÃº«¹úʳƷҩƷÄþ¾²²¿£¨MFDS£©Åú×¼£¬ÓÃÓÚÖÎÁÆÓÉ°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©»òADÇá¶È³Õ´ô£¨ÔçÆÚAD£©µÄ³ÉÄ껼Õß¡£

ÂØ¿¨Ä¹¿ÉÑ¡ÔñÐÔ½áºÏ¿ÉÈÜÐÔA¦Â¾Û¼¯Ì壨ԭÏËά*£©£¬ÒÔ¼°ADÖÐA¦Â°ß¿éµÄÖ÷ÒªÉí·Ö¡ª¡ª²»ÈÜÐÔA¦Â¾Û¼¯Ì壨ÏËά£©£¬´Ó¶ø¼õÉÙ´óÄÔÖеÄA¦ÂÔ­ÏËάºÍA¦Â°ß¿é¡£ÂØ¿¨Ä¹ÊÇÊ׸ö»ñÅúµÄͨ¹ý´Ë»úÖƼõ»º¼²²¡½øÕ¹ËٶȺÍÈÏÖª¼°¹¦Ð§Ë¥Í˵ÄÖÎÁÆÒ©Îï¡£

¾Ý±¨¸æ£¬2021Ä꺫¹ú³Õ´ôÖ¢»¼ÕßÔ¼ÓÐ90ÍòÈ˹£¬ÆäÖÐ65ËêÒÔÉÏÈËȺÖÐÊ®·ÖÖ®Ò»»¼ÓгմôÖ¢£¬Îå·ÖÖ®Ò»»¼ÓÐÇá¶ÈÈÏÖªÕÏ°­²¡£°¢¶û´Äº£Ä¬²¡³Õ´ôÖ¢»¼ÕßÔ¼Õ¼ËùÓгմôÖ¢»¼ÕßµÄ70%¡£¾Ý¹ÀËã£¬Ã¿Î»³Õ´ôÖ¢»¼ÕßµÄÄêƽ¾ù»¤Àí/Ò½ÁÆÓöÈΪ2,110Íòº«Ôª£¨KRW£©£¬¶øÖØÖ¢³Õ´ôÖ¢»¼ÕßµÄÓöÈÔò¸ß´ï3,310Íòº«Ôª¹¡£

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖÐ£¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£ng28ÄϹ¬º«¹ú¹«Ë¾½«ÂôÁ¦¸Ã²úÆ·ÔÚº«¹úµÄ·ÖÏúºÍÐÅÏ¢ÍƹãÔ˶¯¡£

ng28ÄϹ¬º«¹ú¹«Ë¾¶àÄêÀ´Ò»Ö±ÊdzմôÖ¢ÁìÓòµÄÏÈÇý£¬ÖÂÁ¦ÓÚ¿ªÕ¹ÖÖÖÖÔ˶¯Ìá¸ß¼²²¡ÈÏÖª¶È¡£½üÄêÀ´£¬ng28ÄϹ¬º«¹ú¹«Ë¾Óë°üÀ¨Ò½ÁƱ£½¡×¨ÒµÈËÊ¿¡¢Ñ§ÊõÍÅÌå¡¢»¼ÕßȺÌå¡¢»¤ÀíÖÐÐÄ¡¢½¡¿µÌå¼ì¹«Ë¾ÒÔ¼°Õï¶Ï¹«Ë¾µÈÔÚÄڵĸ÷ÀûÒæÏà¹Ø·½ÏàÖú£¬Å¬Á¦´òÔì¿ÉÔö½øADÈÏÖª¡¢ÔçÕï¡¢ÔçÖεijմôÖ¢Éú̬ϵͳ¡£ng28ÄϹ¬º«¹ú¹«Ë¾Ê×ÏȽ«ÔÚ×Ô·ÑÊг¡ÍƳö¸ÃÒ©Æ·£¬²¢¼Æ»®½¨Á¢»¼ÕßÔ®Öú¼Æ»®£¬ÎªÆÚ´ýÖÎÁƵĻ¼ÕßÌṩÂØ¿¨Ä¹£¬²»µ«¶Ô»¼ÕßҲΪËûÃǵÄÕÕÁÏÕßÒÔ¼°º«¹úÉç»á´øÀ´»ý¼«Ó°Ïì¡£

 

*Ô­ÏËά±»ÈÏÊǵ¼ÖÂAD»¼ÕßµÄÄÔËðÉ˵ÄÔªÐ×£¬ÆäËùº¬¶¾ÐÔÊÇA¦ÂÖÐ×î´óµÄ£¬ÔÚÓëÕâÖÖ½øÐÐÐÔË¥ÈõµÄ¼²²¡Ïà¹ØµÄÈÏ֪˥ÍËÖÐÆðÖ÷Òª×÷Óó¡£Ô­ÏËά¶Ô´óÄÔÉñ¾­ÔªÔì³ÉËðÉË£¬½ø¶øͨ¹ý¶àÖÖ»úÖƶÔÈÏÖª¹¦Ð§±¬·¢¸ºÃæÓ°Ïì£¬²»µ«Ôö¼ÓÁ˲»ÈÜÐԦ°߿éµÄÐγÉ£¬²¢ÇÒÔö¼ÓÁ˶ÔÄÔϸ°ûĤºÍÉñ¾­Ï¸°ûÖ®¼ä»òÉñ¾­Ï¸°ûÓëÆäËûϸ°ûÖ®¼äͨ±¨ÐźŵÄÁ¬½ÓµÄÖ±½ÓËðÉË¡£¼õÉÙÔ­ÏËά¿É¼õÉÙ¶Ô´óÄÔÉñ¾­ÔªµÄËðÉ˺ÍÈÏÖª¹¦Ð§ÕÏ°­À´×èÖ¹°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹⁴¡£

 

ýÌåÁªÏµÈË

ng28ÄϹ¬Öêʽ»áÉ繫¹Ø²¿ µç»°£º03-3817-5120

²³½¡¹«Ë¾¹«¹²ÊÂÎñ²¿ ÓÊÏä:public.affairs@biogen.com

 

²Î¿¼ÎÄÏ×

1. Korean dementia observatory 2022: National Institute of Dementia (Korean)
2. Korean dementia observatory 2021: National Institute of Dementia (Korean)
3. Amin L, Harris DA. A¦Â receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
4. Ono K, Tsuji M. Protofibrils of Amyloid-¦Â are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.